{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:30:51Z","timestamp":1793316651575,"version":"4.5.0"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Platinum-based cancer therapy remains a cornerstone of first-line treatment for several solid tumours such as ovarian, testicular, and non-small cell lung cancers, where it has received regulatory approval as both monotherapy and combination regimens. However, the inevitable emergence of resistance has necessitated extensive preclinical and clinical efforts to develop rational platinum-based combinations. The most appealing candidates for combination therapy are those that offer additive and\/or synergistic effects without undesirable overlapping toxicities. Whilst early strategies focussed on co-administration with cytotoxic chemotherapies, recent advances have shifted towards combinations with targeted therapies and immunotherapies, offering improved efficacy and durability of response. In this review, we provide a comprehensive analysis of recent clinical trials evaluating platinum-based combination strategies (excluding radiotherapy) and give an overview of trial concepts that will lead to more refined therapies for cancer. We also highlight emerging dual-drug codelivery nanosystems, platinum-based antibody\u2013drug conjugates (ADCs), and multi-targeted platinum compounds with promising preclinical and\/or clinical evidence. Beyond traditional drug pairings, the improved design strategies of new platinum compounds such as their incorporation into ADCs offer enhanced targeting and reactivity. Whilst promising preclinical examples like trastuzumab-Pt(II) and cetuximab-C8Pt(IV) bring optimism to combinatorial approaches, significant challenges including stability and controlled payload release remain to be addressed before clinical translation. By integrating advances in molecular profiling and rational drug development, platinum-based therapies continue to evolve, offering renewed optimism for overcoming drug resistance and improving patient outcomes, although challenges such as biomarker identification, toxicity management, and treatment costs remain to be fully addressed.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s12032-025-02812-3","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T22:16:04Z","timestamp":1750025764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies"],"prefix":"10.1007","volume":"42","author":[{"given":"Nur Aininie","family":"Yusoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haslina","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Vallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"issue":"1","key":"2812_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2812_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778\u201389. https:\/\/doi.org\/10.1002\/ijc.33588.","journal-title":"Int J Cancer"},{"issue":"2","key":"2812_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1021\/acs.chemrev.8b00685","volume":"119","author":"KJ Franz","year":"2019","unstructured":"Franz KJ, Metzler-Nolte N. Introduction: metals in medicine. Chem Rev. 2019;119(2):727\u20139. https:\/\/doi.org\/10.1021\/acs.chemrev.8b00685.","journal-title":"Chem Rev"},{"issue":"48","key":"2812_CR4","doi-asserted-by":"publisher","first-page":"12888","DOI":"10.1039\/D0SC04082G","volume":"11","author":"EJ Anthony","year":"2020","unstructured":"Anthony EJ, Bolitho EM, Bridgewater HE, Carter OWL, Donnelly JM, Imberti C, et al. Metallodrugs are unique: opportunities and challenges of discovery and development. Chem Sci. 2020;11(48):12888\u2013917. https:\/\/doi.org\/10.1039\/D0SC04082G.","journal-title":"Chem Sci"},{"key":"2812_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2021.214104","volume":"445","author":"I Yousuf","year":"2021","unstructured":"Yousuf I, Bashir M, Arjmand F, Tabassum S. Advancement of metal compounds as therapeutic and diagnostic metallodrugs: current frontiers and future perspectives. Coord Chem Rev. 2021;445: 214104. https:\/\/doi.org\/10.1016\/j.ccr.2021.214104.","journal-title":"Coord Chem Rev"},{"issue":"5191","key":"2812_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/222385a0","volume":"222","author":"B Rosenberg","year":"1969","unstructured":"Rosenberg B, Vancamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222(5191):385\u20136. https:\/\/doi.org\/10.1038\/222385a0.","journal-title":"Nature"},{"key":"2812_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2812_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41581-022-00631-7","volume":"19","author":"C Tang","year":"2023","unstructured":"Tang C, Livingston MJ, Safirstein R, Dong Z. Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat Rev Nephrol. 2023;19(1):53\u201372. https:\/\/doi.org\/10.1038\/s41581-022-00631-7.","journal-title":"Nat Rev Nephrol"},{"issue":"15","key":"2812_CR9","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869\u201383. https:\/\/doi.org\/10.1038\/onc.2011.384.","journal-title":"Oncogene"},{"issue":"3","key":"2812_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1124\/pr.111.005637","volume":"64","author":"DW Shen","year":"2012","unstructured":"Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3):706\u201321. https:\/\/doi.org\/10.1124\/pr.111.005637.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"2812_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/bf00257742","volume":"9","author":"AH Calvert","year":"1982","unstructured":"Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140\u20137. https:\/\/doi.org\/10.1007\/bf00257742.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2812_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3747\/co.v18i1.708","volume":"18","author":"T Alcindor","year":"2011","unstructured":"Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011;18(1):18\u201325. https:\/\/doi.org\/10.3747\/co.v18i1.708.","journal-title":"Curr Oncol"},{"issue":"5","key":"2812_CR13","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","volume":"116","author":"TC Johnstone","year":"2016","unstructured":"Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev. 2016;116(5):3436\u201386. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00597.","journal-title":"Chem Rev"},{"issue":"6","key":"2812_CR14","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/1078-0432.Ccr-07-2176","volume":"14","author":"H Choy","year":"2008","unstructured":"Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res. 2008;14(6):1633\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-2176.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2812_CR15","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1517\/13543780903362437","volume":"18","author":"A Bhargava","year":"2009","unstructured":"Bhargava A, Vaishampayan UN. Satraplatin: leading the new generation of oral platinum agents. Expert Opin Investig Drugs. 2009;18(11):1787\u201397. https:\/\/doi.org\/10.1517\/13543780903362437.","journal-title":"Expert Opin Investig Drugs"},{"key":"2812_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.891652","author":"TB Emran","year":"2022","unstructured":"Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MFR, et al. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.891652.","journal-title":"Front Oncol"},{"issue":"23","key":"2812_CR17","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343. https:\/\/doi.org\/10.18632\/oncotarget.16723.","journal-title":"Oncotarget"},{"issue":"7","key":"2812_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nbt.1549","volume":"27","author":"J Leh\u00e1r","year":"2009","unstructured":"Leh\u00e1r J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27(7):659\u201366. https:\/\/doi.org\/10.1038\/nbt.1549.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2812_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","volume":"14","author":"JS Lopez","year":"2017","unstructured":"Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 2017;14(1):57\u201366. https:\/\/doi.org\/10.1038\/nrclinonc.2016.96.","journal-title":"Nat Rev Clin Oncol"},{"key":"2812_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cbpa.2014.02.003","volume":"19","author":"N Muhammad","year":"2014","unstructured":"Muhammad N, Guo Z. Metal-based anticancer chemotherapeutic agents. Curr Opin Chem Biol. 2014;19:144\u201353. https:\/\/doi.org\/10.1016\/j.cbpa.2014.02.003.","journal-title":"Curr Opin Chem Biol"},{"key":"2812_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.102925","volume":"88","author":"S Ghosh","year":"2019","unstructured":"Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88: 102925. https:\/\/doi.org\/10.1016\/j.bioorg.2019.102925.","journal-title":"Bioorg Chem"},{"issue":"4","key":"2812_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/annonc\/mdx011","volume":"28","author":"A Karam","year":"2017","unstructured":"Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, et al. Fifth ovarian cancer consensus conference of the gynecologic cancer interGroup: first-line interventions. Ann Oncol. 2017;28(4):711\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdx011.","journal-title":"Ann Oncol"},{"key":"2812_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:192\u2013237. https:\/\/doi.org\/10.1093\/annonc\/mdy275.","journal-title":"Ann Oncol"},{"issue":"30","key":"2812_CR24","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/jco.2017.74.6065","volume":"35","author":"N Hanna","year":"2017","unstructured":"Hanna N, Johnson D, Temin S Jr, Brahmer SBJ, Ellis PM, et al. Systemic therapy for stage IV non\u2013small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(30):3484\u2013515. https:\/\/doi.org\/10.1200\/jco.2017.74.6065.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2812_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00280-021-04235-z","volume":"87","author":"WW Ma","year":"2021","unstructured":"Ma WW, Zhu M, Lam ET, Diamond JR, Dy GK, Fisher GA, et al. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. Cancer Chemother Pharmacol. 2021;87(6):779\u201388. https:\/\/doi.org\/10.1007\/s00280-021-04235-z.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"2812_CR26","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1634\/theoncologist.2013-0126","volume":"18","author":"JM Gibson","year":"2013","unstructured":"Gibson JM, Alzghari S, Ahn C, Trantham H, La-Beck NM. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist. 2013;18(9):1022\u201331. https:\/\/doi.org\/10.1634\/theoncologist.2013-0126.","journal-title":"Oncologist"},{"issue":"15_suppl","key":"2812_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1200\/JCO.2019.37.15_suppl.516","volume":"37","author":"P Sharma","year":"2019","unstructured":"Sharma P, Kimler BF, O\u2019Dea A, Nye LE, Wang YY, Yoder R, et al. Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320). J Clin Oncol. 2019;37(15_suppl):516\u2013516. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.516.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2812_CR28","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ejca.2014.11.017","volume":"51","author":"S Mahner","year":"2015","unstructured":"Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell\u2019Anna T, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Eur J Cancer. 2015;51(3):352\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2014.11.017.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2812_CR29","doi-asserted-by":"publisher","first-page":"e669","DOI":"10.1002\/onco.13598","volume":"26","author":"MG McNamara","year":"2021","unstructured":"McNamara MG, Bridgewater J, Palmer DH, Faluyi O, Wasan H, Patel A, et al. A Phase Ib Study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08). Oncologist. 2021;26(4):e669\u201378. https:\/\/doi.org\/10.1002\/onco.13598.","journal-title":"Oncologist"},{"issue":"1","key":"2812_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023;30(1):102\u201310. https:\/\/doi.org\/10.1002\/jhbp.1219.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"8","key":"2812_CR31","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/2767-9764.Crc-23-0230","volume":"3","author":"HC Wilbur","year":"2023","unstructured":"Wilbur HC, Durham JN, Lim SJ, Purtell K, Bever KM, Laheru DA, et al. Gemcitabine, docetaxel, capecitabine, cisplatin, irinotecan as first-line treatment for metastatic pancreatic cancer. Cancer Res Commun. 2023;3(8):1672\u20137. https:\/\/doi.org\/10.1158\/2767-9764.Crc-23-0230.","journal-title":"Cancer Res Commun"},{"issue":"11","key":"2812_CR32","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/2767-9764.Crc-22-0343","volume":"2","author":"ES Christenson","year":"2022","unstructured":"Christenson ES, Lim SJ, Durham J, De Jesus-Acosta A, Bever K, Laheru D, et al. Cell-free DNA predicts prolonged response to multi-agent chemotherapy in pancreatic ductal adenocarcinoma. Cancer Res Commun. 2022;2(11):1418\u201325. https:\/\/doi.org\/10.1158\/2767-9764.Crc-22-0343.","journal-title":"Cancer Res Commun"},{"issue":"6","key":"2812_CR33","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824\u201330. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0270.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2812_CR34","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/annonc\/mdr441","volume":"23","author":"L Gladieff","year":"2012","unstructured":"Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol. 2012;23(5):1185\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdr441.","journal-title":"Ann Oncol"},{"key":"2812_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lungcan.2018.01.007","volume":"117","author":"DR Spigel","year":"2018","unstructured":"Spigel DR, Hainsworth JD, Shipley DL, Mekhail TM, Zubkus JD, Waterhouse DM, et al. Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: a phase II trial of the Sarah Cannon Oncology Research Consortium. Lung Cancer. 2018;117:38\u201343. https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.007.","journal-title":"Lung Cancer"},{"key":"2812_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211022905","author":"F Grossi","year":"2021","unstructured":"Grossi F, Ja\u015bkiewicz P, Ferreira M, Czy\u017cewicz G, Kowalski D, Ciuffreda L, et al. Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Ther Adv Med Oncol. 2021. https:\/\/doi.org\/10.1177\/17588359211022905.","journal-title":"Ther Adv Med Oncol"},{"key":"2812_CR37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.phrs.2016.08.002","volume":"111","author":"C P\u00e9rez-Ram\u00edrez","year":"2016","unstructured":"P\u00e9rez-Ram\u00edrez C, Ca\u00f1adas-Garre M, Alnatsha A, Villar E, Delgado JR, Faus-D\u00e1der MJ, et al. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. Pharmacol Res. 2016;111:877\u201384. https:\/\/doi.org\/10.1016\/j.phrs.2016.08.002.","journal-title":"Pharmacol Res"},{"issue":"12","key":"2812_CR38","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1111\/1759-7714.13683","volume":"11","author":"C de Jong","year":"2020","unstructured":"de Jong C, Herder GJM, Deneer VHM. Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: design of the multicenter PGxLUNG study. Thorac Cancer. 2020;11(12):3634\u201340. https:\/\/doi.org\/10.1111\/1759-7714.13683.","journal-title":"Thorac Cancer"},{"issue":"10","key":"2812_CR39","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","volume":"54","author":"H-Y Min","year":"2022","unstructured":"Min H-Y, Lee H-Y. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54(10):1670\u201394. https:\/\/doi.org\/10.1038\/s12276-022-00864-3.","journal-title":"Exp Mol Med"},{"issue":"10","key":"2812_CR40","first-page":"3034","volume":"8","author":"R Dagher","year":"2002","unstructured":"Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8(10):3034\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2812_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58. https:\/\/doi.org\/10.1186\/s12943-018-0782-4.","journal-title":"Mol Cancer"},{"key":"2812_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.737951","volume":"8","author":"X Meng","year":"2021","unstructured":"Meng X, Gao JZ, Gomendoza SMT, Li JW, Yang S. Recent advances of WEE1 inhibitors and statins in cancers with p53 mutations. Front Med (Lausanne). 2021;8: 737951. https:\/\/doi.org\/10.3389\/fmed.2021.737951.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"2812_CR43","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1158\/1535-7163.Mct-09-0463","volume":"8","author":"H Hirai","year":"2009","unstructured":"Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009;8(11):2992\u20133000. https:\/\/doi.org\/10.1158\/1535-7163.Mct-09-0463.","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"2812_CR44","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.Ccr-20-0219","volume":"26","author":"AM Oza","year":"2020","unstructured":"Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marm\u00e9 F, Provencher D, et al. A Biomarker-enriched, randomized phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer. Clin Cancer Res. 2020;26(18):4767\u201376. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0219.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2812_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","volume":"22","author":"H Jin","year":"2023","unstructured":"Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2023;22(3):213\u201334. https:\/\/doi.org\/10.1038\/s41573-022-00615-z.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2812_CR46","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2174\/0929867321666141216125528","volume":"22","author":"L Garuti","year":"2015","unstructured":"Garuti L, Roberti M, Bottegoni G. Multi-kinase inhibitors. Curr Med Chem. 2015;22(6):695\u2013712. https:\/\/doi.org\/10.2174\/0929867321666141216125528.","journal-title":"Curr Med Chem"},{"issue":"10","key":"2812_CR47","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020;19(10):711\u201336. https:\/\/doi.org\/10.1038\/s41573-020-0076-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2812_CR48","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo J, Lord CJ, Serra V, Tutt A, Balma\u00f1a J, Castroviejo-Bermejo M, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30(9):1437\u201347. https:\/\/doi.org\/10.1093\/annonc\/mdz192.","journal-title":"Ann Oncol"},{"issue":"4","key":"2812_CR49","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/carcin\/bgs393","volume":"34","author":"H Cheng","year":"2013","unstructured":"Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis. 2013;34(4):739\u201349. https:\/\/doi.org\/10.1093\/carcin\/bgs393.","journal-title":"Carcinogenesis"},{"issue":"1","key":"2812_CR50","doi-asserted-by":"publisher","first-page":"12876","DOI":"10.1038\/s41598-017-13232-3","volume":"7","author":"CB Prasad","year":"2017","unstructured":"Prasad CB, Prasad SB, Yadav SS, Pandey LK, Singh S, Pradhan S, et al. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep. 2017;7(1):12876. https:\/\/doi.org\/10.1038\/s41598-017-13232-3.","journal-title":"Sci Rep"},{"issue":"15_suppl","key":"2812_CR51","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1200\/jco.2015.33.15_suppl.1082","volume":"33","author":"K Miller","year":"2015","unstructured":"Miller K, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, et al. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: final efficacy results of Hoosier Oncology Group BRE09-146. J Clin Oncol. 2015;33(15_suppl):1082\u20131082. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.1082.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2812_CR52","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ygyno.2017.12.029","volume":"148","author":"HJ Gray","year":"2018","unstructured":"Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, et al. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018;148(3):507\u201314. https:\/\/doi.org\/10.1016\/j.ygyno.2017.12.029.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2812_CR53","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497\u2013509. https:\/\/doi.org\/10.1016\/s1470-2045(18)30111-6.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2812_CR54","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","volume":"33","author":"CE Geyer","year":"2022","unstructured":"Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O\u2019Shaughnessy J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022;33(4):384\u201394. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.009.","journal-title":"Ann Oncol"},{"issue":"3","key":"2812_CR55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/jco.18.00264","volume":"37","author":"TK Owonikoko","year":"2019","unstructured":"Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL 3rd, Srkalovic G, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol. 2019;37(3):222\u20139. https:\/\/doi.org\/10.1200\/jco.18.00264.","journal-title":"J Clin Oncol"},{"key":"2812_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.105171","volume":"114","author":"MJ Jelinek","year":"2021","unstructured":"Jelinek MJ, Foster NR, Zoroufy AJ, Schwartz GK, Munster PN, Seiwert TY, et al. A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. Oral Oncol. 2021;114: 105171. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.105171.","journal-title":"Oral Oncol"},{"key":"2812_CR57","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211059601","author":"JP Ayoub","year":"2021","unstructured":"Ayoub JP, Wildiers H, Friedlander M, Arun BK, Han HS, Puhalla S, et al. Safety and efficacy of veliparib plus carboplatin\/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1\/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial. Ther Adv Med Oncol. 2021. https:\/\/doi.org\/10.1177\/17588359211059601.","journal-title":"Ther Adv Med Oncol"},{"key":"2812_CR58","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","volume":"629","author":"JE Abraham","year":"2024","unstructured":"Abraham JE, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C, et al. The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer. Nature. 2024;629:1142\u20138. https:\/\/doi.org\/10.1038\/s41586-024-07384-2.","journal-title":"Nature"},{"issue":"16_suppl","key":"2812_CR59","doi-asserted-by":"publisher","first-page":"TPS619","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS619","volume":"40","author":"L Drewett","year":"2022","unstructured":"Drewett L, Lucey R, Pinilla KA, Grybowicz L, Wulff J, Dayimu A, et al. PARTNER: A randomized, phase II\/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and\/or germline BRCA-mutated breast cancer. J Clin Oncol. 2022;40(16_suppl):TPS619. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS619.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2812_CR60","doi-asserted-by":"publisher","first-page":"9055","DOI":"10.1200\/JCO.2020.38.15_suppl.9055","volume":"38","author":"M Koczywas","year":"2020","unstructured":"Koczywas M, Frankel PH, Riess JW, El-Khoueiry AB, Villaruz LC, Leong S, et al. Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors\/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin. J Clin Oncol. 2020;38(15_suppl):9055\u20139055. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9055.","journal-title":"J Clin Oncol"},{"key":"2812_CR61","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/397563","volume":"2015","author":"DJ Son","year":"2015","unstructured":"Son DJ, Hong JE, Ban JO, Park JH, Lee HL, Gu SM, et al. Synergistic inhibitory effects of cetuximab and cisplatin on human colon cancer cell growth via inhibition of the ERK-dependent EGF receptor signaling pathway. Biomed Res Int. 2015;2015: 397563. https:\/\/doi.org\/10.1155\/2015\/397563.","journal-title":"Biomed Res Int"},{"issue":"7","key":"2812_CR62","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1634\/theoncologist.2017-0618","volume":"23","author":"V Trieu","year":"2018","unstructured":"Trieu V, Pinto H, Riess JW, Lira R, Luciano R, Coty J, et al. Weekly docetaxel, cisplatin, and cetuximab in palliative treatment of patients with squamous cell carcinoma of the head and neck. Oncologist. 2018;23(7):764-e786. https:\/\/doi.org\/10.1634\/theoncologist.2017-0618.","journal-title":"Oncologist"},{"issue":"4","key":"2812_CR63","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/s1470-2045(20)30755-5","volume":"22","author":"J Guigay","year":"2021","unstructured":"Guigay J, Aup\u00e9rin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014\u201301 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463\u201375. https:\/\/doi.org\/10.1016\/s1470-2045(20)30755-5.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2812_CR64","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41416-019-0584-5","volume":"121","author":"N Colombo","year":"2019","unstructured":"Colombo N, Zaccarelli E, Baldoni A, Frezzini S, Scambia G, Palluzzi E, et al. Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer. Br J Cancer. 2019;121(9):744\u201350. https:\/\/doi.org\/10.1038\/s41416-019-0584-5.","journal-title":"Br J Cancer"},{"issue":"1","key":"2812_CR65","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ygyno.2019.10.012","volume":"156","author":"KN Moore","year":"2020","unstructured":"Moore KN, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, O\u2019Cearbhaill RE, et al. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020;156(1):13\u201322. https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.012.","journal-title":"Gynecol Oncol"},{"key":"2812_CR66","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2023.03.018","volume":"186","author":"C Thibault","year":"2023","unstructured":"Thibault C, Fl\u00e9chon A, Albiges L, Joly C, Barthelemy P, Gross-Goupil M, et al. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: results of a prospective phase II trial (BEVABEL-GETUG\/AFU24). Eur J Cancer. 2023;186:83\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2023.03.018.","journal-title":"Eur J Cancer"},{"key":"2812_CR67","doi-asserted-by":"publisher","first-page":"ii42","DOI":"10.1093\/annonc\/mdx091.039","volume":"28","author":"S Thomas","year":"2017","unstructured":"Thomas S, Doebele RC, Spigel D, Tehfe M, Reck M, Verma S, et al. A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): final results from squamous pts. Ann Oncol. 2017;28:ii42\u20133. https:\/\/doi.org\/10.1093\/annonc\/mdx091.039.","journal-title":"Ann Oncol"},{"issue":"1","key":"2812_CR68","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","volume":"34","author":"M Yan","year":"2015","unstructured":"Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34(1):157\u201364. https:\/\/doi.org\/10.1007\/s10555-015-9552-6.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"2812_CR69","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10120-018-0861-7","volume":"22","author":"S Mondaca","year":"2019","unstructured":"Mondaca S, Margolis M, Sanchez-Vega F, Jonsson P, Riches JC, Ku GY, et al. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer. 2019;22(2):355\u201362. https:\/\/doi.org\/10.1007\/s10120-018-0861-7.","journal-title":"Gastric Cancer"},{"issue":"13","key":"2812_CR70","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/jco.20.01204","volume":"39","author":"M Piccart","year":"2021","unstructured":"Piccart M, Procter M, Fumagalli D, Azambuja ED, Clark E, Ewer MS, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years follow-up. J Clin Oncol. 2021;39(13):1448\u201357. https:\/\/doi.org\/10.1200\/jco.20.01204.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2812_CR71","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1200\/JCO.2023.41.16_suppl.4057","volume":"41","author":"AD Wagner","year":"2023","unstructured":"Wagner AD, Grabsch HI, Mauer M, Romario UF, Kang Y-K, Bouche O, et al. Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): first results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group. J Clin Oncol. 2023;41(16):4057\u20134057. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.4057.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2812_CR72","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","volume":"9","author":"J Fuentes-Antr\u00e1s","year":"2023","unstructured":"Fuentes-Antr\u00e1s J, Genta S, Vijenthira A, Siu LL. Antibody-drug conjugates: in search of partners of choice. Trends in Cancer. 2023;9(4):339\u201354. https:\/\/doi.org\/10.1016\/j.trecan.2023.01.003.","journal-title":"Trends in Cancer"},{"issue":"1","key":"2812_CR73","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","volume":"151","author":"KN Moore","year":"2018","unstructured":"Moore KN, O\u2019Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, et al. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018;151(1):46\u201352. https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.017.","journal-title":"Gynecol Oncol"},{"key":"2812_CR74","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jinorgbio.2019.110780","volume":"199","author":"V De Solar","year":"2019","unstructured":"De Solar V, Contel M. Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer. J Inorg Biochem. 2019;199:180. https:\/\/doi.org\/10.1016\/j.jinorgbio.2019.110780.","journal-title":"J Inorg Biochem"},{"key":"2812_CR75","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.biopha.2015.05.013","volume":"73","author":"R Huang","year":"2015","unstructured":"Huang R, Sun Y, Zhang XY, Sun BW, Wang QC, Zhu J. Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery. Biomed Pharmacother. 2015;73:116\u201322. https:\/\/doi.org\/10.1016\/j.biopha.2015.05.013.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"2812_CR76","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jpha.2023.11.002","volume":"14","author":"X Yin","year":"2024","unstructured":"Yin X, Zhuang Y, Song H, Xu Y, Zhang F, Cui J, et al. Antibody-platinum (IV) prodrugs conjugates for targeted treatment of cutaneous squamous cell carcinoma. J Pharm Anal. 2024;14(3):389\u2013400. https:\/\/doi.org\/10.1016\/j.jpha.2023.11.002.","journal-title":"J Pharm Anal"},{"key":"2812_CR77","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.biomaterials.2014.10.069","volume":"39","author":"J Ahn","year":"2015","unstructured":"Ahn J, Miura Y, Yamada N, Chida T, Liu X, Kim A, et al. Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. Biomaterials. 2015;39:23\u201330. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.10.069.","journal-title":"Biomaterials"},{"key":"2812_CR78","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jconrel.2015.05.271","volume":"210","author":"S Zalba","year":"2015","unstructured":"Zalba S, Contreras AM, Haeri A, Ten Hagen TL, Navarro I, Koning G, et al. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. J Control Release. 2015;210:26\u201338. https:\/\/doi.org\/10.1016\/j.jconrel.2015.05.271.","journal-title":"J Control Release"},{"issue":"24","key":"2812_CR79","doi-asserted-by":"publisher","first-page":"12278","DOI":"10.1039\/c3nr04268e","volume":"5","author":"E Falvo","year":"2013","unstructured":"Falvo E, Tremante E, Fraioli R, Leonetti C, Zamparelli C, Boffi A, et al. Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. Nanoscale. 2013;5(24):12278\u201385. https:\/\/doi.org\/10.1039\/c3nr04268e.","journal-title":"Nanoscale"},{"issue":"7","key":"2812_CR80","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.1021\/acsami.7b13431","volume":"10","author":"CY Lin","year":"2018","unstructured":"Lin CY, Yang SJ, Peng CL, Shieh MJ. Panitumumab-conjugated and platinum-cored pH-sensitive apoferritin nanocages for colorectal cancer-targeted therapy. ACS Appl Mater Interfaces. 2018;10(7):6096\u2013106. https:\/\/doi.org\/10.1021\/acsami.7b13431.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"3","key":"2812_CR81","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","volume":"133","author":"A Davis","year":"2014","unstructured":"Davis A, Tinker AV, Friedlander M. \u201cPlatinum resistant\u201d; ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133(3):624\u201331. https:\/\/doi.org\/10.1016\/j.ygyno.2014.02.038.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2812_CR82","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/jco.23.01771","volume":"42","author":"JS Laurent","year":"2024","unstructured":"Laurent JS, Liu JF. Treatment approaches for platinum-resistant ovarian cancer. J Clin Oncol. 2024;42(2):127\u201333. https:\/\/doi.org\/10.1200\/jco.23.01771.","journal-title":"J Clin Oncol"},{"issue":"22","key":"2812_CR83","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/cmdc.202000391","volume":"15","author":"NA Yusoh","year":"2020","unstructured":"Yusoh NA, Ahmad H, Gill MR. Combining PARP inhibition with platinum, ruthenium or gold complexes for cancer therapy. ChemMedChem. 2020;15(22):2121\u201335. https:\/\/doi.org\/10.1002\/cmdc.202000391.","journal-title":"ChemMedChem"},{"issue":"6","key":"2812_CR84","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1158\/1078-0432.Ccr-16-1546","volume":"23","author":"JM Lee","year":"2017","unstructured":"Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, et al. Sequence-specific pharmacokinetic and pharmacodynamic phase I\/Ib study of Olaparib tablets and carboplatin in women\u2019s cancer. Clin Cancer Res. 2017;23(6):1397\u2013406. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1546.","journal-title":"Clin Cancer Res"},{"key":"2812_CR85","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.160573","author":"LG Coffman","year":"2022","unstructured":"Coffman LG, Orellana TJ, Liu T, Frisbie LG, Normolle D, Griffith K, et al. Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer. JCI Insight. 2022. https:\/\/doi.org\/10.1172\/jci.insight.160573.","journal-title":"JCI Insight"},{"issue":"13","key":"2812_CR86","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1158\/0008-5472.Can-10-4111","volume":"71","author":"EA Stronach","year":"2011","unstructured":"Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 2011;71(13):4412\u201322. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-4111.","journal-title":"Cancer Res"},{"issue":"15","key":"2812_CR87","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1200\/JCO.2017.35.15_suppl.5541","volume":"35","author":"S Tjulandin","year":"2017","unstructured":"Tjulandin S, Fedyanin M, Vladimirov VI, Kostorov V, Lisyanskaya AS, Krikunova L, et al. A multicenter phase II study of the efficacy and safety of quisinostat (an HDAC inhibitor) in combination with paclitaxel and carboplatin chemotherapy (CT) in patients (pts) with recurrent platinum resistant high grade serous epithelial ovarian, primarily peritoneal or fallopian tube carcinoma cancer (OC). J Clin Oncol. 2017;35(15):5541\u20135541. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.5541.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2812_CR88","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/jcm13030897","volume":"13","author":"H Meteran","year":"2024","unstructured":"Meteran H, Knudsen A, J\u00f8rgensen TL, Nielsen D, Herrstedt J. Carboplatin plus paclitaxel in combination with the histone deacetylate inhibitor, vorinostat, in patients with recurrent platinum-sensitive ovarian cancer. J Clin Med. 2024;13(3):897. https:\/\/doi.org\/10.3390\/jcm13030897.","journal-title":"J Clin Med"},{"issue":"2","key":"2812_CR89","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.Ccr-18-1539","volume":"25","author":"MT Dillon","year":"2019","unstructured":"Dillon MT, Grove L, Newbold KL, Shaw H, Brown NF, Mendell J, et al. Patritumab with cetuximab plus platinum-containing therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: an open-label, phase Ib study. Clin Cancer Res. 2019;25(2):487\u201395. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-1539.","journal-title":"Clin Cancer Res"},{"key":"2812_CR90","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejca.2019.08.017","volume":"123","author":"MD Forster","year":"2019","unstructured":"Forster MD, Dillon MT, Kocsis J, Remen\u00e1r E, Pajkos G, Rolland F, et al. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a randomised phase II study. Eur J Cancer. 2019;123:36\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.017.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2812_CR91","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/oncolo\/oyac275","volume":"28","author":"RT Penson","year":"2023","unstructured":"Penson RT, Ambrosio AJ, Whalen CA, Krasner CN, Konstantinopoulos PA, Bradley C, et al. Phase II trials of iniparib (BSI-201) in combination with gemcitabine and carboplatin in patients with recurrent ovarian cancer. Oncologist. 2023;28(3):252\u20137. https:\/\/doi.org\/10.1093\/oncolo\/oyac275.","journal-title":"Oncologist"},{"issue":"12","key":"2812_CR92","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrclinonc.2013.177","volume":"10","author":"J Mateo","year":"2013","unstructured":"Mateo J, Ong M, Tan DSP, Gonzalez MA, de Bono JS. Appraising iniparib, the PARP inhibitor that never was\u2014what must we learn? Nat Rev Clin Oncol. 2013;10(12):688\u201396. https:\/\/doi.org\/10.1038\/nrclinonc.2013.177.","journal-title":"Nat Rev Clin Oncol"},{"key":"2812_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101825","volume":"39","author":"J Li","year":"2024","unstructured":"Li J, Hu H, He J, Hu Y, Liu M, Cao B, et al. Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer. Transl Oncol. 2024;39: 101825. https:\/\/doi.org\/10.1016\/j.tranon.2023.101825.","journal-title":"Transl Oncol"},{"issue":"11","key":"2812_CR94","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368. https:\/\/doi.org\/10.1038\/s41577-020-0306-5.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2812_CR95","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1039\/D1CS00417D","volume":"51","author":"S Sen","year":"2022","unstructured":"Sen S, Won M, Levine MS, Noh Y, Sedgwick AC, Kim JS, et al. Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future. Chem Soc Rev. 2022;51(4):1212\u201333. https:\/\/doi.org\/10.1039\/D1CS00417D.","journal-title":"Chem Soc Rev"},{"issue":"2","key":"2812_CR96","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1021\/acs.chemrev.8b00396","volume":"119","author":"B Englinger","year":"2019","unstructured":"Englinger B, Pirker C, Heffeter P, Terenzi A, Kowol CR, Keppler BK, et al. Metal drugs and the anticancer immune response. Chem Rev. 2019;119(2):1519\u2013624. https:\/\/doi.org\/10.1021\/acs.chemrev.8b00396.","journal-title":"Chem Rev"},{"issue":"1","key":"2812_CR97","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023;8(1):320. https:\/\/doi.org\/10.1038\/s41392-023-01522-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2812_CR98","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"issue":"2","key":"2812_CR99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):39. https:\/\/doi.org\/10.1208\/s12248-021-00574-0.","journal-title":"AAPS J"},{"issue":"11","key":"2812_CR100","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/jco.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-Year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992\u20138. https:\/\/doi.org\/10.1200\/jco.22.01989.","journal-title":"J Clin Oncol"},{"key":"2812_CR101","doi-asserted-by":"publisher","first-page":"S1420","DOI":"10.1016\/j.annonc.2020.10.494","volume":"31","author":"J Menis","year":"2020","unstructured":"Menis J, Bironzo P, Radj G, Greillier L, Monnet I, Livi L, et al. 9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis\/carboplatin with or without pembrolizumab (NCT02580994). Ann Oncol. 2020;31:S1420. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.494.","journal-title":"Ann Oncol"},{"issue":"6","key":"2812_CR102","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/s1470-2045(20)30169-8","volume":"21","author":"YY Janjigian","year":"2020","unstructured":"Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821\u201331. https:\/\/doi.org\/10.1016\/s1470-2045(20)30169-8.","journal-title":"Lancet Oncol"},{"issue":"21","key":"2812_CR103","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/jco.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Cs\u0151szi T, et al. Pembrolizumab or placebo plus etoposide and platinum as first-Line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369\u201379. https:\/\/doi.org\/10.1200\/jco.20.00793.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2812_CR104","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1111\/cas.14980","volume":"112","author":"H Horinouchi","year":"2021","unstructured":"Horinouchi H, Nogami N, Saka H, Nishio M, Tokito T, Takahashi T, et al. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. Cancer Sci. 2021;112(8):3255\u201365. https:\/\/doi.org\/10.1111\/cas.14980.","journal-title":"Cancer Sci"},{"issue":"6","key":"2812_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252665","volume":"16","author":"CS Walsh","year":"2021","unstructured":"Walsh CS, Kamrava M, Rogatko A, Kim S, Li A, Cass I, et al. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoS ONE. 2021;16(6): e0252665. https:\/\/doi.org\/10.1371\/journal.pone.0252665.","journal-title":"PLoS ONE"},{"issue":"7","key":"2812_CR106","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/s1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, Matsubara N, G\u00e9czi L, Cheng SY, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931\u201345. https:\/\/doi.org\/10.1016\/s1470-2045(21)00152-2.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2812_CR107","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003122","volume":"9","author":"JB Liao","year":"2021","unstructured":"Liao JB, Gwin WR, Urban RR, Hitchcock-Bernhardt KM, Coveler AL, Higgins DM, et al. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. J Immunother Cancer. 2021;9(9): e003122. https:\/\/doi.org\/10.1136\/jitc-2021-003122.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"2812_CR108","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1158\/2767-9764.Crc-22-0147","volume":"2","author":"EL Barber","year":"2022","unstructured":"Barber EL, Chen S, Pineda MJ, Robertson SE, Hill EK, Teoh D, et al. Clinical and biological activity of chemoimmunotherapy in advanced endometrial adenocarcinoma: a phase II trial of the Big Ten Cancer Research Consortium. Cancer Res Commun. 2022;2(10):1293\u2013303. https:\/\/doi.org\/10.1158\/2767-9764.Crc-22-0147.","journal-title":"Cancer Res Commun"},{"issue":"6_suppl","key":"2812_CR109","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1200\/JCO.2023.41.6_suppl.165","volume":"41","author":"AI Chin","year":"2023","unstructured":"Chin AI, Ly A, Rodriguez S, Sachdeva A, Zomorodian N, Zhang H, et al. Updated results of a phase Ib single-center study of pembrolizumab in combination with chemotherapy in patients with locally advanced or metastatic small cell\/neuroendocrine cancers of the prostate and urothelium. J Clin Oncol. 2023;41(6_suppl):165\u2013165. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.165.","journal-title":"J Clin Oncol"},{"issue":"10391","key":"2812_CR110","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/s0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/s0140-6736(23)00727-4.","journal-title":"Lancet"},{"issue":"11","key":"2812_CR111","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/s1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395. https:\/\/doi.org\/10.1016\/s1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"key":"2812_CR112","doi-asserted-by":"publisher","first-page":"S1247","DOI":"10.1016\/j.annonc.2022.07.1627","volume":"33","author":"D Isla","year":"2022","unstructured":"Isla D, Arriola E, Garcia Campelo MR, Diz Tain P, Marti Blanco C, Lopez-Brea Piqueras MM, et al. 1532P Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): preliminary efficacy results. Ann Oncol. 2022;33:S1247\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1627.","journal-title":"Ann Oncol"},{"issue":"8","key":"2812_CR113","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, He AR, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid"},{"issue":"12","key":"2812_CR114","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/jco.18.01042","volume":"37","author":"N Ready","year":"2019","unstructured":"Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol. 2019;37(12):992\u20131000. https:\/\/doi.org\/10.1200\/jco.18.01042.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2812_CR115","doi-asserted-by":"publisher","first-page":"16066","DOI":"10.1002\/cam4.6260","volume":"12","author":"DH Lee","year":"2023","unstructured":"Lee DH, Kim HR, Keam B, Kato K, Kuboki Y, Gao H, et al. Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma. Cancer Med. 2023;12(15):16066\u201375. https:\/\/doi.org\/10.1002\/cam4.6260.","journal-title":"Cancer Med"},{"issue":"15","key":"2812_CR116","doi-asserted-by":"publisher","first-page":"e20546","DOI":"10.1200\/JCO.2019.37.15_suppl.e20546","volume":"37","author":"N Xu","year":"2019","unstructured":"Xu N, Ying K, Wang Z, Liu Y, Jiang H, Zhou H, et al. Phase Ib study of sintilimab in combination with chemotherapy for 1L advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37(15):e20546. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e20546.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2812_CR117","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 2021;16(9):1501\u201311. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.011.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"2812_CR118","doi-asserted-by":"publisher","first-page":"S1014","DOI":"10.1016\/j.jtho.2021.08.339","volume":"16","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zeng L, Zhang X, Zhou Y, Zhang B, Jiang W, et al. P15.02 Toripalimab and platinum-doublet chemotherapy as neoadjuvant therapy for potentially resectable non-small cell lung cancer. J Thorac Oncol. 2021;16(10):S1014\u20135. https:\/\/doi.org\/10.1016\/j.jtho.2021.08.339.","journal-title":"J Thorac Oncol"},{"key":"2812_CR119","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.lungcan.2021.09.004","volume":"161","author":"JM Clarke","year":"2021","unstructured":"Clarke JM, Patel JD, Robert F, Kio EA, Thara E, Ross Camidge D, et al. Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: a phase 1 dose escalation study. Lung Cancer. 2021;161:180\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2021.09.004.","journal-title":"Lung Cancer"},{"key":"2812_CR120","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2147\/cmar.S325856","volume":"15","author":"J Ahn","year":"2023","unstructured":"Ahn J, Nagasaka M. Spotlight on cemiplimab-rwlc in the treatment of non-small cell lung cancer (NSCLC): focus on patient selection and considerations. Cancer Manag Res. 2023;15:627\u201334. https:\/\/doi.org\/10.2147\/cmar.S325856.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2812_CR121","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156. https:\/\/doi.org\/10.1038\/s41392-023-01407-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2812_CR122","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10637-015-0216-8","volume":"33","author":"R Chakrabarty","year":"2015","unstructured":"Chakrabarty R, Tran H, Selvaggi G, Hagerman A, Thompson B, Coffey M. The oncolytic virus, pelareorep, as a novel anticancer agent: a review. Invest New Drugs. 2015;33(3):761\u201374. https:\/\/doi.org\/10.1007\/s10637-015-0216-8.","journal-title":"Invest New Drugs"},{"issue":"6","key":"2812_CR123","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/mt.2016.66","volume":"24","author":"AM Noonan","year":"2016","unstructured":"Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, et al. Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol Ther. 2016;24(6):1150\u20138. https:\/\/doi.org\/10.1038\/mt.2016.66.","journal-title":"Mol Ther"},{"issue":"4","key":"2812_CR124","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00280-017-3260-6","volume":"79","author":"D Mahalingam","year":"2017","unstructured":"Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R, et al. A phase II study of REOLYSIN(\u00ae) (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2017;79(4):697\u2013703. https:\/\/doi.org\/10.1007\/s00280-017-3260-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2812_CR125","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","volume":"22","author":"D-I Jang","year":"2021","unstructured":"Jang D-I, Lee A-H, Shin H-Y, Song H-R, Park J-H, Kang T-B, et al. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):2719.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2812_CR126","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1038\/s41467-022-33719-6","volume":"13","author":"PK Paik","year":"2022","unstructured":"Paik PK, Luo J, Ai N, Kim R, Ahn L, Biswas A, et al. Phase I trial of the TNF-\u03b1 inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nat Commun. 2022;13(1):6095. https:\/\/doi.org\/10.1038\/s41467-022-33719-6.","journal-title":"Nat Commun"},{"issue":"1","key":"2812_CR127","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28. https:\/\/doi.org\/10.1186\/s13045-022-01247-x.","journal-title":"J Hematol Oncol"},{"key":"2812_CR128","doi-asserted-by":"publisher","first-page":"1368103","DOI":"10.3389\/fimmu.2024.1368103","volume":"15","author":"BJ Koeneman","year":"2024","unstructured":"Koeneman BJ, Schreibelt G, Gorris MAJ, Hins-de Bree S, Westdorp H, Ottevanger PB, et al. Dendritic cell vaccination combined with carboplatin\/paclitaxel for metastatic endometrial cancer patients: results of a phase I\/II trial. Front Immunol. 2024;15:1368103. https:\/\/doi.org\/10.3389\/fimmu.2024.1368103.","journal-title":"Front Immunol"},{"issue":"3","key":"2812_CR129","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ygyno.2021.07.003","volume":"162","author":"D Cibula","year":"2021","unstructured":"Cibula D, Rob L, Mallmann P, Knapp P, Klat J, Chovanec J, et al. Dendritic cell-based immunotherapy (DCVAC\/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): a randomized, open-label, phase 2 trial. Gynecol Oncol. 2021;162(3):652\u201360. https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.003.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"2812_CR130","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1136\/ijgc-2023-004812","volume":"33","author":"RW Holloway","year":"2023","unstructured":"Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, et al. A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant\/refractory ovarian cancer. Int J Gynecol Cancer. 2023;33(9):1458\u201363. https:\/\/doi.org\/10.1136\/ijgc-2023-004812.","journal-title":"Int J Gynecol Cancer"},{"issue":"27","key":"2812_CR131","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1200\/jco.2010.33.8566","volume":"29","author":"S Pignata","year":"2011","unstructured":"Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011;29(27):3628\u201335. https:\/\/doi.org\/10.1200\/jco.2010.33.8566.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2812_CR132","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa0802656.","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"2812_CR133","doi-asserted-by":"publisher","first-page":"6029","DOI":"10.1200\/jco.2013.31.15_suppl.6029","volume":"31","author":"LJ Wirth","year":"2013","unstructured":"Wirth LJ, Dakhil SR, Kornek G, Axelrod R, Adkins D, Pant S, et al. PARTNER: A randomized phase II study of docetaxel\/cisplatin (doc\/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN). J Clin Oncol. 2013;31(15_suppl):6029\u20136029. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.6029.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2812_CR134","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1200\/jco.2013.31.15_suppl.5502","volume":"31","author":"A Cervantes-Ruiperez","year":"2013","unstructured":"Cervantes-Ruiperez A, Hoskins P, Vergote I, Eisenhauer EA, Ghatage P, Carey M, et al. Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemotherapy for advanced epithelial ovarian cancer (EOC): A GCIG study of NCIC CTG, EORTC-GCG, and GEICO. J Clin Oncol. 2013;31(15_suppl):5502\u20135502. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.5502.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2812_CR135","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","volume":"28","author":"PJ Br\u00f6ckelmann","year":"2017","unstructured":"Br\u00f6ckelmann PJ, M\u00fcller H, Casasnovas O, Hutchings M, von Tresckow B, J\u00fcrgens M, et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017;28(6):1352\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdx072.","journal-title":"Ann Oncol"},{"issue":"34","key":"2812_CR136","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1200\/jco.2010.30.5771","volume":"28","author":"A Josting","year":"2010","unstructured":"Josting A, M\u00fcller H, Borchmann P, Baars JW, Metzner B, D\u00f6hner H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma. J Clin Oncol. 2010;28(34):5074\u201380. https:\/\/doi.org\/10.1200\/jco.2010.30.5771.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2812_CR137","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/annonc\/mdq575","volume":"22","author":"G Daugaard","year":"2011","unstructured":"Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011;22(5):1054\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdq575.","journal-title":"Ann Oncol"},{"issue":"2","key":"2812_CR138","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.clgc.2018.11.013","volume":"17","author":"YY Tan","year":"2019","unstructured":"Tan YY, Al-Bubseeree B, Irvine D, MacDonald G, McQuaker G, Parker A, et al. High-dose chemotherapy in relapsed or refractory metastatic germ-cell cancer: the Scotland experience. Clin Genitourin Cancer. 2019;17(2):125\u201331. https:\/\/doi.org\/10.1016\/j.clgc.2018.11.013.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"2812_CR139","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1021\/acsnano.6b06040","volume":"11","author":"B Pelaz","year":"2017","unstructured":"Pelaz B, Alexiou C, Alvarez-Puebla RA, Alves F, Andrews AM, Ashraf S, et al. Diverse applications of nanomedicine. ACS Nano. 2017;11(3):2313\u201381. https:\/\/doi.org\/10.1021\/acsnano.6b06040.","journal-title":"ACS Nano"},{"issue":"5","key":"2812_CR140","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/wnan.1390","volume":"8","author":"X Duan","year":"2016","unstructured":"Duan X, He C, Kron SJ, Lin W. Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016;8(5):776\u201391. https:\/\/doi.org\/10.1002\/wnan.1390.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"2","key":"2812_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1410","volume":"9","author":"Q Cheng","year":"2017","unstructured":"Cheng Q, Liu Y. Multifunctional platinum-based nanoparticles for biomedical applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(2): e1410. https:\/\/doi.org\/10.1002\/wnan.1410.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"2812_CR142","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/581363","volume":"2012","author":"GP Stathopoulos","year":"2012","unstructured":"Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Deliv. 2012;2012: 581363. https:\/\/doi.org\/10.1155\/2012\/581363.","journal-title":"J Drug Deliv"},{"issue":"4","key":"2812_CR143","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/bjc.2011.6","volume":"104","author":"R Plummer","year":"2011","unstructured":"Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, et al. A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer. 2011;104(4):593\u20138. https:\/\/doi.org\/10.1038\/bjc.2011.6.","journal-title":"Br J Cancer"},{"issue":"3","key":"2812_CR144","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00280-017-3254-4","volume":"79","author":"T Doi","year":"2017","unstructured":"Doi T, Hamaguchi T, Shitara K, Iwasa S, Shimada Y, Harada M, et al. NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK\/PD analysis. Cancer Chemother Pharmacol. 2017;79(3):569\u201378. https:\/\/doi.org\/10.1007\/s00280-017-3254-4.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2812_CR145","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.Ccr-17-1114","volume":"24","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Grilley-Olson JE, Combest AJ, Sharma N, Tran RH, Bobe I, et al. Phase Ib\/II Trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine in patients with advanced solid tumors. Clin Cancer Res. 2018;24(1):43\u201351. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-1114.","journal-title":"Clin Cancer Res"},{"issue":"33","key":"2812_CR146","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.18632\/oncotarget.27684","volume":"11","author":"SR Volovat","year":"2020","unstructured":"Volovat SR, Ciuleanu TE, Koralewski P, Olson JEG, Croitoru A, Koynov K, et al. A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. Oncotarget. 2020;11(33):3105\u201317. https:\/\/doi.org\/10.18632\/oncotarget.27684.","journal-title":"Oncotarget"},{"key":"2812_CR147","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0959-8049(20)31164-3","volume":"138","author":"A Osada","year":"2020","unstructured":"Osada A, Mangel L, Fijuth J, \u017burawski B, Ursulovic T, Nikolin B, et al. Phase IIa\/IIb clinical trial of NC-6004 (Nanoparticle Cisplatin) plus pembrolizumab in patients with head and neck cancer (HNSCC) who have failed platinum or a platinum-containing regimen. Eur J Cancer. 2020;138:S35. https:\/\/doi.org\/10.1016\/S0959-8049(20)31164-3.","journal-title":"Eur J Cancer"},{"key":"2812_CR148","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.biomaterials.2014.10.044","volume":"37","author":"L Cai","year":"2015","unstructured":"Cai L, Xu G, Shi C, Guo D, Wang X, Luo J. Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: a synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials. 2015;37:456\u201368. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.10.044.","journal-title":"Biomaterials"},{"issue":"6","key":"2812_CR149","doi-asserted-by":"publisher","first-page":"41440","DOI":"10.1002\/app.41440","volume":"132","author":"J Li","year":"2015","unstructured":"Li J, Li Z, Li M, Zhang H, Xie Z. Synergistic effect and drug-resistance relief of paclitaxel and cisplatin caused by co-delivery using polymeric micelles. J Appl Polym Sci. 2015;132(6):41440. https:\/\/doi.org\/10.1002\/app.41440.","journal-title":"J Appl Polym Sci"},{"issue":"1","key":"2812_CR150","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1080\/10717544.2016.1236849","volume":"24","author":"J Yang","year":"2016","unstructured":"Yang J, Ju Z, Dong S. Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer. Drug Deliv. 2016;24(1):792\u20139. https:\/\/doi.org\/10.1080\/10717544.2016.1236849.","journal-title":"Drug Deliv"},{"key":"2812_CR151","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/ijn.S115136","volume":"12","author":"B Liu","year":"2017","unstructured":"Liu B, Han L, Liu J, Han S, Chen Z, Jiang L. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer. Int J Nanomed. 2017;12:955\u201368. https:\/\/doi.org\/10.2147\/ijn.S115136.","journal-title":"Int J Nanomed"},{"key":"2812_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.532457","volume":"11","author":"T Yu","year":"2020","unstructured":"Yu T, Li Y, Gu X, Li Q. Development of a hyaluronic acid-based nanocarrier incorporating doxorubicin and cisplatin as a pH-sensitive and CD44-targeted anti-breast cancer drug delivery system. Front Pharmacol. 2020;11: 532457. https:\/\/doi.org\/10.3389\/fphar.2020.532457.","journal-title":"Front Pharmacol"},{"issue":"96","key":"2812_CR153","doi-asserted-by":"publisher","first-page":"94160","DOI":"10.1039\/C6RA17213J","volume":"6","author":"H Li","year":"2016","unstructured":"Li H, Yu H, Zhu C, Hu J, Du M, Zhang F, et al. Cisplatin and doxorubicin dual-loaded mesoporous silica nanoparticles for controlled drug delivery. RSC Adv. 2016;6(96):94160\u20139. https:\/\/doi.org\/10.1039\/C6RA17213J.","journal-title":"RSC Adv"},{"issue":"2","key":"2812_CR154","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1021\/acs.chemrev.8b00271","volume":"119","author":"RG Kenny","year":"2019","unstructured":"Kenny RG, Marmion CJ. Toward multi-targeted platinum and ruthenium drugs\u2014A new paradigm in cancer drug treatment regimens? Chem Rev. 2019;119(2):1058\u2013137. https:\/\/doi.org\/10.1021\/acs.chemrev.8b00271.","journal-title":"Chem Rev"},{"issue":"16","key":"2812_CR155","doi-asserted-by":"publisher","first-page":"12132","DOI":"10.1021\/acs.jmedchem.1c00770","volume":"64","author":"P Fronik","year":"2021","unstructured":"Fronik P, Poetsch I, Kastner A, Mendrina T, Hager S, Hohenwallner K, et al. Structure-activity relationships of triple-action platinum(IV) prodrugs with albumin-binding properties and immunomodulating ligands. J Med Chem. 2021;64(16):12132\u201351. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00770.","journal-title":"J Med Chem"},{"key":"2812_CR156","doi-asserted-by":"publisher","first-page":"6735","DOI":"10.1039\/b916715c","volume":"44","author":"D Griffith","year":"2009","unstructured":"Griffith D, Morgan MP, Marmion CJ. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. Chem Commun. 2009;44:6735\u20137. https:\/\/doi.org\/10.1039\/b916715c.","journal-title":"Chem Commun"},{"key":"2812_CR157","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jinorgbio.2013.03.011","volume":"124","author":"JP Parker","year":"2013","unstructured":"Parker JP, Nimir H, Griffith DM, Duff B, Chubb AJ, Brennan MP, et al. A novel platinum complex of the histone deacetylase inhibitor belinostat: rational design, development and in vitro cytotoxicity. J Inorg Biochem. 2013;124:70\u20137. https:\/\/doi.org\/10.1016\/j.jinorgbio.2013.03.011.","journal-title":"J Inorg Biochem"},{"issue":"6","key":"2812_CR158","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jinorgbio.2011.03.001","volume":"105","author":"DM Griffith","year":"2011","unstructured":"Griffith DM, Duff B, Suponitsky KY, Kavanagh K, Morgan MP, Egan D, et al. Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity. J Inorg Biochem. 2011;105(6):793\u20139. https:\/\/doi.org\/10.1016\/j.jinorgbio.2011.03.001.","journal-title":"J Inorg Biochem"},{"issue":"2","key":"2812_CR159","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1021\/tx200525n","volume":"25","author":"B Liskova","year":"2012","unstructured":"Liskova B, Zerzankova L, Novakova O, Kostrhunova H, Travnicek Z, Brabec V. Cellular response to antitumor cis-Dichlorido platinum(II) complexes of CDK inhibitor Bohemine and its analogues. Chem Res Toxicol. 2012;25(2):500\u20139. https:\/\/doi.org\/10.1021\/tx200525n.","journal-title":"Chem Res Toxicol"},{"issue":"5","key":"2812_CR160","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1039\/C5SC00015G","volume":"6","author":"DYQ Wong","year":"2015","unstructured":"Wong DYQ, Lim JH, Ang WH. Induction of targeted necrosis with HER2-targeted platinum(iv) anticancer prodrugs. Chem Sci. 2015;6(5):3051\u20136. https:\/\/doi.org\/10.1039\/C5SC00015G.","journal-title":"Chem Sci"},{"key":"2812_CR161","doi-asserted-by":"publisher","first-page":"114505","DOI":"10.1016\/j.biopha.2023.114505","volume":"161","author":"J Gong","year":"2023","unstructured":"Gong J, Shi T, Liu J, Pei Z, Liu J, Ren X, et al. Dual-drug codelivery nanosystems: an emerging approach for overcoming cancer multidrug resistance. Biomed Pharmacother. 2023;161:114505. https:\/\/doi.org\/10.1016\/j.biopha.2023.114505.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2812_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44385-024-00003-9","volume":"2","author":"Q Liao","year":"2025","unstructured":"Liao Q, Zhang Y, Chu Y, Ding Y, Liu Z, Zhao X, et al. Application of artificial intelligence in drug-target interactions prediction: a review. npj Biomed Innov. 2025;2(1):1. https:\/\/doi.org\/10.1038\/s44385-024-00003-9.","journal-title":"npj Biomed Innov"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02812-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02812-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T15:03:24Z","timestamp":1751555004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02812-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":162,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2812"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02812-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"262"}}